Cellular and physiological mechanisms of new-onset diabetes mellitus after solid organ transplantation

Diabetic Medicine

Volumn 29, Issue 7, 2012, Pages

  Dong, M ^a,b   Parsaik, A K ^a   Eberhardt, N L ^a   Basu, A ^a   Cosio, F G ^a   Kudva, Y C ^a  

^a MAYO CLINIC   (United States)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Diabetes mellitus; Mechanism; New onset; Organ transplantation

Indexed keywords

CYCLOSPORIN; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; RAPAMYCIN; TACROLIMUS;

ARTICLE; CARDIOVASCULAR RISK; CELL DIVISION; CELL SURVIVAL; CYTOMEGALOVIRUS; DIABETES MELLITUS; GRAFT SURVIVAL; HEPATITIS C VIRUS; HEREDITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY GRAFT; NEW ONSET DIABETES AFTER TRANSPLANTATION; NONHUMAN; ORGAN TRANSPLANTATION; PANCREAS ISLET BETA CELL; PATHOGENESIS; PHARMACOGENETICS; SIGNAL TRANSDUCTION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HEART TRANSPLANTATION; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INSULIN; INSULIN RESISTANCE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; ORGAN TRANSPLANTATION; RISK FACTORS;

EID: 84862680509     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2012.03617.x     Document Type: Article

References (58)

1. Balla A, Chobanian M. New-onset diabetes after transplantation: a review of recent literature. Curr Opin Organ Transplant 2009; 14: 375-379.
2. Pham PT, Pham PC, Lipshutz GS, Wilkinson AH. New onset diabetes mellitus after solid organ transplantation. Endocrinol Metab Clin North Am 2007; 36: 873-890.
3. Cosio FG, Kudva Y, van der Velde M, Larson TS, Textor SC, Griffin MD et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005; 67: 2415-2421.
4. Kuo HT, Sampaio MS, Vincenti F, Bunnapradist S. Associations of pretransplant diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OPTN/UNOS) database. Am J Kidney Dis 2010; 56: 1127-39.
5. Kuo HT, Sampaio MS, Ye X, Reddy P, Martin P, Bunnapradist S. Risk factors for new-onset diabetes mellitus in adult liver transplant recipients, an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing database. Transplantation 2010; 89: 1134-1140.
6. Ye X, Kuo HT, Sampaio MS, Jiang Y, Reddy P, Bunnapradist S. Risk factors for development of new-onset diabetes mellitus in adult heart transplant recipients. Transplantation 2010; 89: 1526-32.
7. Hjelmesaeth J, Asberg A, Muller F, Hartmann A, Jenssen T. New-onset posttransplantation diabetes mellitus: insulin resistance or insulinopenia? Impact of immunosuppressive drugs, cytomegalovirus and hepatitis C virus infection. Curr Diabetes Rev 2005; 1: 1-10.
8. Hamer RA, Chow CL, Ong AC, McKane WS. Polycystic kidney disease is a risk factor for new-onset diabetes after transplantation. Transplantation 2007; 83: 36-40.
9. Kuo HT, Lau C, Sampaio MS, Bunnapradist S. Pretransplant risk factors for new-onset diabetes mellitus after transplant in pediatric liver transplant recipients. Liver Transpl 2010; 16: 1249-1256.
10. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 2002; 25: 583-592.
11. Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG. Steroid diabetes - a sign of overtreatment with steroids in the renal graft recipient? Scand J Urol Nephrol Suppl 1980; 54: 135-138.
12. Penfornis A, Kury-Paulin S. Immunosuppressive drug-induced diabetes. Diabetes Metab 2006; 32: 539-546.
13. Midtvedt K, Hjelmesaeth J, Hartmann A, Lund K, Paulsen D, Egeland T et al. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. J Am Soc Nephrol 2004; 15: 3233-9.
14. van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? Eur J Clin Invest 2009; 39: 81-93.
15. Ullrich S, Berchtold S, Ranta F, Seebohm G, Henke G, Lupescu A et al. Serum- and glucocorticoid-inducible kinase 1 (SGK1) mediates glucocorticoid-induced inhibition of insulin secretion. Diabetes 2005; 54: 1090-1099.
16. Zawalich WS, Tesz GJ, Yamazaki H, Zawalich KC, Philbrick W. Dexamethasone suppresses phospholipase C activation and insulin secretion from isolated rat islets. Metabolism 2006; 55: 35-42.
17. Davani B, Portwood N, Bryzgalova G, Reimer MK, Heiden T, Ostenson CG et al. Aged transgenic mice with increased glucocorticoid sensitivity in pancreatic beta-cells develop diabetes. Diabetes 2004; 53(Suppl 1): S51-S59.
18. Nir T, Melton DA, Dor Y. Recovery from diabetes in mice by beta cell regeneration. J Clin Invest 2007; 117: 2553-2561.
19. Rood PP, Bottino R, Balamurugan AN, Fan Y, Cooper DK, Trucco M. Facilitating physiologic self-regeneration: a step beyond islet cell replacement. Pharm Res 2006; 23: 227-242.
20. Heit JJ. Calcineurin/NFAT signaling in the beta-cell: from diabetes to new therapeutics. Bioessays 2007; 29: 1011-1021.
21. Plaumann S, Blume R, Borchers S, Steinfelder HJ, Knepel W, Oetjen E. Activation of the dual-leucine-zipper-bearing kinase and induction of beta-cell apoptosis by the immunosuppressive drug cyclosporin A. Mol Pharmacol 2008; 73: 652-659.
22. Soleimanpour SA, Crutchlow MF, Ferrari AM, Raum JC, Groff DN, Rankin MM et al. Calcineurin signaling regulates human islet β-cell survival. J Biol Chem 2010; 285: 40050-40059.
23. Boots JM, van Duijnhoven EM, Christiaans MH, Wolffenbuttel BH, van Hooff JP. Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol 2002; 13: 221-227.
24. Rickels MR, Mueller R, Teff KL, Naji A β-Cell secretory capacity and demand in recipients of islet, pancreas, and kidney transplants. J Clin Endocrinol Metab 2010; 95: 1238-1246.
25. Dufer M, Krippeit-Drews P, Lembert N, Idahl LA, Drews G. Diabetogenic effect of cyclosporin A is mediated by interference with mitochondrial function of pancreatic B-cells. Mol Pharmacol 2001; 60: 873-879.
26. Rostambeigi N, Lanza IR, Dzeja PP, Deeds MC, Irving BA, Reddi HV et al. Unique cellular and mitochondrial defects mediate FK506-induced islet beta-cell dysfunction. Transplantation 2011; 91: 615-623.
27. Fuhrer DK, Kobayashi M, Jiang H. Insulin release and suppression by tacrolimus, rapamycin and cyclosporin A are through regulation of the ATP-sensitive potassium channel. Diabetes Obes Metab 2001; 3: 393-402.
28. Radu RG, Fujimoto S, Mukai E, Takehiro M, Shimono D, Nabe K et al. Tacrolimus suppresses glucose-induced insulin release from pancreatic islets by reducing glucokinase activity. Am J Physiol Endocrinol Metab 2005; 288: E365-E371.
29. Uchizono Y, Iwase M, Nakamura U, Sasaki N, Goto D, Iida MT. Tacrolimus impairment of insulin secretion in isolated rat islets occurs at multiple distal sites in stimulus-secretion coupling. Endocrinology 2004; 145: 2264-2272.
30. Wahlstrom HE, Akimoto R, Endres D, Kolterman O, Moossa AR. Recovery and hypersecretion of insulin and reversal of insulin resistance after withdrawal of short-term cyclosporine treatment. Transplantation 1992; 53: 1190-1195.
31. Ozbay L, Smidt K, Mortensen D, Carstens J, Jorgensen K, Rungby J. Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells. Br J Pharmacol 2011; 162: 136-146.
32. Vodenik B, Rovira J, Campistol JM. Mammalian target of rapamycin and diabetes: what does the current evidence tell us? Transplant Proc 2009; 41(6 Suppl): S31-S38.
33. Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008; 19: 1411-1418.
34. Araki M, Flechner SM, Ismail HR, Flechner LM, Zhou L, Derweesh IH et al. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs. Transplantation 2006; 81: 335-341.
35. Shimodahira M, Fujimoto S, Mukai E, Nakamura Y, Nishi Y, Sasaki M et al. Rapamycin impairs metabolism-secretion coupling in rat pancreatic islets by suppressing carbohydrate metabolism. J Endocrinol 2010; 204: 37-46.
36. Balcazar N, Sathyamurthy A, Elghazi L, Gould A, Weiss A, Shiojima I et al. mTORC1 activation regulates beta-cell mass and proliferation by modulation of cyclin D2 synthesis and stability. J Biol Chem 2009; 284: 7832-7842.
37. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22: 159-168.
38. Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004; 165: 1499-1508.
39. Bamoulid J, Courivaud C, Deschamps M, Mercier P, Ferrand C, Penfornis A et al. IL-6 promoter polymorphism-174 is associated with new-onset diabetes after transplantation. J Am Soc Nephrol 2006; 17: 2333-2340.
40. Dutkiewicz G, Domanski L, Pawlik A, Binczak-Kuleta A, Safranow K, Ciechanowicz A et al. Polymorphisms of superoxide dismutase, glutathione peroxidase and catalase genes in patients with post-transplant diabetes mellitus. Arch Med Res 2010; 41: 350-355.
41. Chang HR, Yang SF, Tsai JP, Hsieh MC, Wu SW, Tsai HC et al. Plasminogen activator inhibitor-1 5G/5G genotype is a protecting factor preventing posttransplant diabetes mellitus. Clin Chim Acta 2010; 412: 322-326.
42. Kurzawski M, Dziewanowski K, Kedzierska K, Gornik W, Banas A, Drozdzik M. Association of calpain-10 gene polymorphism and posttransplant diabetes mellitus in kidney transplant patients medicated with tacrolimus. Pharmacogenomics J 2010; 10: 120-125.
43. Numakura K, Satoh S, Tsuchiya N, Horikawa Y, Inoue T, Kakinuma H et al. Incidence and risk factors of clinical characteristics, tacrolimus pharmacokinetics, and related genomic polymorphisms for posttransplant diabetes mellitus in the early stage of renal transplant recipients. Transplant Proc 2005; 37: 1865-1867.
44. Ergun I, Keven K, Sengul S, Karabulut HG, Kurultak I, Soypacaci Z et al. Endothelial nitric oxide synthase gene intron 4 polymorphism predicts new onset diabetes mellitus after transplantation in kidney allograft recipients treated with cyclosporin A. Int Urol Nephrol 2011; 43: 543-548.
45. Jeong KH, Moon JY, Chung JH, Kim YH, Lee TW et al. Significant associations between CCL5 gene polymorphisms and post-transplantational diabetes mellitus in Korean renal allograft recipients. Am J Nephrol 2010; 32: 356-361.
46. Ghisdal L, Baron C, Le Meur Y, Lionet A, Halimi JM, Rerolle JP et al. TCF7L2 polymorphism associates with new-onset diabetes after transplantation. J Am Soc Nephrol 2009; 20: 2459-2467.
47. Kang ES, Kim MS, Kim YS, Kim CH, Han SJ, Chun SW et al. A polymorphism in the zinc transporter gene SLC30A8 confers resistance against posttransplantation diabetes mellitus in renal allograft recipients. Diabetes 2008; 57: 1043-1047.
48. Kang ES, Kim MS, Kim YS, Hur KY, Han SJ, Nam CM et al. A variant of the transcription factor 7-like 2 (TCF7L2) gene and the risk of posttransplantation diabetes mellitus in renal allograft recipients. Diabetes Care 2008; 31: 63-68.
49. Chakkera HA, Hanson RL, Raza SM, DiStefano JK, Millis MP, Heilman RL et al. Pilot study: association of traditional and genetic risk factors and new-onset diabetes mellitus following kidney transplantation. Transplant Proc 2009; 41: 4172-4177.
50. Torres-Romero LF, Santiago-Delpin EA, de Echegaray S, Solis DR, Rodriguez-Trinidad AT, Gonzalez-Caraballo ZA et al. HLA is not predictive of posttransplant diabetes mellitus. Transplant Proc 2006; 38: 914-915.
51. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II. Clin Pharmacokinet 2010; 49: 207-221.
52. Barrera-Pulido L, Aguilera-Garcia I, Docobo-Perez F, Alamo-Martinez JM, Pareja-Ciuro F, Nunez-Roldan A et al. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients. Transplant Proc 2008; 40: 2949-2951.
53. Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248: 564-577.
54. Ghisdal L, Bouchta NB, Broeders N, Crenier L, Hoang AD, Abramowicz D et al. Conversion from tacrolimus to cyclosporine A for new-onset diabetes after transplantation: a single-centre experience in renal transplanted patients and review of the literature. Transpl Int 2008; 21: 146-151.
55. Shihab FS, Waid TH, Conti DJ, Yang H, Holman MJ, Mulloy LC et al. Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF Study. Transplantation 2008; 85: 1261-1269.
56. Beckebaum S, Klein C, Varghese J, Sotiropoulos GC, Saner F, Schmitz K et al. Renal function and cardiovascular risk profile after conversion from cyclosporin to tacrolimus: prospective study in 80 liver transplant recipients. Aliment Pharmacol Ther 2009; 30: 834-842.
57. Tan J, Yang S, Cai J, Guo J, Huang L, Wu Z et al. Simultaneous islet and kidney transplantation in seven patients with type 1 diabetes and end-stage renal disease using a glucocorticoid-free immunosuppressive regimen with alemtuzumab induction. Diabetes 2008; 57: 2666-2671.
58. Jaber JJ, Feustel PJ, Elbahloul O, Conti AD, Gallichio MH, Conti DJ. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol. Clin Transplant 2007; 21: 101-109.